Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is a heterogeneous disorder that develops as a result of relatively inappropriate insulin secretion often in the setting of defective insulin action (insulin resistance). The factors responsible for insufficient insulin production in patients with type 2 diabetes are complex and are thought to involve a combination of genetic and metabolic defects, including chronic hyperglycemia, increased levels of free fatty acids, and dyslipidemia, which contribute to an inability to sustain adequate insulin secretion, defective β-cell proliferation, and/or increased β-cell apoptosis (1). Studies of the natural history of type 2 diabetes inform us that a progressive decline in β-cell function is common in diabetic patients independent of the method of treatment (2). Hence, new approaches are clearly needed that not only control metabolic abnormalities such as dyslipidemia and hyperglycemia, but that also preserve β-cell function and mass, perhaps by increasing the number of newly formed β-cells and/or decreasing β-cell death. Emerging experimental evidence has confirmed that elevated levels of glucose and specific monounsaturated fatty acids may be deleterious to β-cell survival in short-term studies of human islets (3). Although detailed information about the relative balance of β-cell proliferation and apoptosis in pancreases from subjects with type 2 diabetes is not available, recent autopsy data suggest that a combination of inappropriately decreased β-cell mass and increased β-cell apoptosis in the diabetic pancreas may be more common than previously appreciated (4, 5). Hence, absolute or relative deficiency of β-cells occurs paradoxically at a time when enhanced functional β-cell mass and increased insulin production is needed to overcome insulin resistance. Not surprisingly, the progressive deterioration in β-cell function that accompanies type 2 diabetes has sparked interest in identifying factors that either promote formation of new β-cells or inhibit the death of vulnerable β-cells (1). Experimental studies carried out predominantly in rodents have demonstrated that IGFs, hepatocyte growth factor, pituitary adenylate cyclase-activating polypeptide, PTHrP, epidermal growth factor receptor agonists in combination with gastrin, and incompletely characterized proteins such as islet neogenesis-associated protein, are capable of enhancing β-cell mass in the setting of experimental diabetes. Hence, prolonged administration of these agents may expand β-cell mass, ultimately leading to increased insulin secretion and improved glycemic control. Similarly, growth factors may also expand the number of human islet cells in experimental culture systems (6, 7). Nevertheless, none of these proteins has been demonstrated to rapidly lower blood glucose and improve metabolic control in preclinical models of diabetes independent of their chronic effects on islet proliferation or β-cell survival. Hence, pharmaceutical development of molecules exhibiting β-cell growth factor-like activity that do not concomitantly acutely lower blood glucose remains highly challenging as it may take weeks or more likely months to determine their potential efficacy in diabetic human subjects. New data presented in the article by Farilla et al. (8) in this issue of Endocrinology now demonstrate that glucagon-like peptide-1 (GLP-1), a gut hormone derived from enteroendocrine L cells, inhibits cell death in freshly isolated human islets cultured in vitro for 5 d. The antiapoptotic effects of GLP-1 have previously been demonstrated in diabetic rodents, islet cell lines, purified rat β-cells, and heterologous cells expressing the GLP-1 receptor (9–12). Intriguingly, GLP-1 receptor activation also enhances neuronal survival in diverse cellular and animal models of neuronal toxicity, and elimination of GLP-1 receptor function in mice is associated with increased neurotoxicity after peripheral administration of kainic acid (13, 14). Furthermore, the antiapoptotic actions of GLP-1 are essential for β-cell survival in response to cellular injury, as mice with a disruption of the GLP-1 receptor gene exhibit enhanced β-cell death and more severe hyperglycemia after exposure to streptozotocin (10). Farilla et al. (8) added GLP-1 (10 nm) to human islet cells isolated from three independent donors and observed preserved islet morphology in the GLP-1-treated islets, whereas control islets exhibited a greater degree of degradation and loss of three-dimensional structure. GLP-1 treatment was also associated with reduced morphological features of β-cell apoptosis (nuclear condensation and fragmentation) and decreased expression of active caspase-3, an enzyme that plays an essential role in the final pathway leading to programmed cell death. The authors found that GLP-1-treated islets exhibited a progressive increase in the levels of the prosurvival protein bcl-2, which likely contributed to the antiapoptotic actions of GLP-1 in the islet cultures. GLP-
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It also promotes proliferation and reduces apoptosis of pancreatic β-cells, thereby maintaining their quality and functionality.130,218”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [218]
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 2×
“As GLP-1 treatment of human diabetic subjects improves metabolic control resulting in reduction of hyperglycemia and a decrease in circulating fatty acids (25), GLP-1 may also indirectly attenuate islet glucotoxicity and lipotoxicity, thereby resulting in healthier -cells and reduced -cell death (Fig.”
BackgroundXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Self-citationFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 3×
“glucose-dependent insulin secretion (8).”
BackgroundInfluentialSelective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · cited 2×
“glycemia after exposure to streptozotocin (10).”
BackgroundSelf-citationEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Self-citation
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Rubino, F., Forgione, A., Cummings, D. E., Vix, M., Gnuli, D., Mingrone, G., Castagneto, M., & Marescaux, J. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000224726.61448.1b · Cited by 928
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Augeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050261p · Cited by 624
Gastric Bypass for Obesity: Mechanisms of Weight Loss and Diabetes Resolution
Cummings, D. E., Overduin, J., & Foster-Schubert, K. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0433 · Cited by 503
Yusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 446
Self-citationMechanisms of β-Cell Death in Type 2 Diabetes
Donath, M. Y., Ehses, J. A., Maedler, K., Schumann, D. M., Ellingsgaard, H., Eppler, E., & Reinecke, M. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s108 · Cited by 444
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
Ahrén, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2782 · Cited by 419
BARNETT, A. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01178.x · Cited by 391
Islet Inflammation in Type 2 Diabetes
Donath, M. Y., Schumann, D. M., Faulenbach, M., Ellingsgaard, H., Perren, A., & Ehses, J. A. (2008) · Diabetes Care · doi:10.2337/dc08-s243 · Cited by 334
Translational Control and the Unfolded Protein Response
Wek, R. C., & Cavener, D. R. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1764 · Cited by 305
Eckhardt, M., Langkopf, E., Mark, M., Tadayyon, M., Thomas, L., Nar, H., Pfrengle, W., Guth, B., Lotz, R., Sieger, P., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701280z · Cited by 284
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290
Self-citationSleeve gastrectomy and type 2 diabetes mellitus: a systematic review
Gill, R. S., Birch, D. W., Shi, X., Sharma, A. M., & Karmali, S. (2010) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2010.07.011 · Cited by 256
Li, Y., Cao, X., Li, L.-X., Brubaker, P. L., Edlund, H., & Drucker, D. J. (2005) · Diabetes · doi:10.2337/diabetes.54.2.482 · Cited by 247
Self-citationProliferation of sorted human and rat beta cells
Parnaud, G., Bosco, D., Berney, T., Pattou, F., Kerr-Conte, J., Donath, M. Y., Bruun, C., Mandrup-Poulsen, T., Billestrup, N., & Halban, P. A. (2007) · Diabetologia · doi:10.1007/s00125-007-0855-1 · Cited by 232
“In our study, the GLP-1 analogue liraglutide significantly increased proliferation of rat beta cells only after 48 h but not 24 h of treatment, but instantly increased GSIS, in keeping with its well known insulinotrophic action [40–43].”
BackgroundIs Type 2 Diabetes an Operable Intestinal Disease?
Rubino, F. (2008) · Diabetes Care · doi:10.2337/dc08-s271 · Cited by 232
Biologic actions and therapeutic potential of the proglucagon-derived peptides
Drucker, D. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0017 · Cited by 230
Self-citationPaniagua, J. A., de la Sacristana, A. G., Sánchez, E., Romero, I., Vidal-Puig, A., Berral, F. J., Escribano, A., Moyano, M. J., Peréz-Martinez, P., López-Miranda, J., et al. (2007) · Journal of the American College of Nutrition · doi:10.1080/07315724.2007.10719633 · Cited by 227
Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in Adipocytes
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609088200 · Cited by 216
Guideline for management of postmeal glucose
Ceriello, A., Colagiuri, S., Gerich, J., & Tuomilehto, J. (2008) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.01.012 · Cited by 213
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
G-protein-coupled receptors and islet function—Implications for treatment of type 2 diabetes
Winzell, M. S., & Ahrén, B. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.08.002 · Cited by 183
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
Kirby, M., Yu, D. M. T., O'connor, S., & Gorrell, M. D. (2010) · Clinical Science · doi:10.1042/cs20090047 · Cited by 179
Partial pancreatectomy in adult humans does not provoke β-cell regeneration
Menge, B. A., Tannapfel, A., Belyaev, O., Drescher, R., Müller, C., Uhl, W., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes · doi:10.2337/db07-1294 · Cited by 173
“like peptide 1 (GLP-1), as well as the lactogenic hormones placental lactogen and prolactin have been suggested to enhance beta-cell replication [44-46].”
BackgroundFunctional Assessment of Pancreatic β-Cell Area in Humans
Meier, J. J., Menge, B. A., Breuer, T. G. K., Müller, C. A., Tannapfel, A., Uhl, W., Schmidt, W. E., & Schrader, H. (2009) · Diabetes · doi:10.2337/db08-1611 · Cited by 163
Gautier, J., Fetita, S., Sobngwi, E., & Salaün-Martin, C. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70190-8 · Cited by 163
Karasik, A., Aschner, P. J., Katzeff, H. L., Davies, M. J., & Stein, P. P. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x261069 · Cited by 163
Johnson, J. D., Ao, Z., Ao, P., Li, H., Dai, L.-J., He, Z., Tee, M., Potter, K. J., Klimek, A. M., Meloche, R. M., et al. (2009) · Cell Transplantation · doi:10.3727/096368909x471198 · Cited by 155
Life and death decisions of the pancreatic β-cell: the role of fatty acids
Newsholme, P., Keane, D., Welters, H. J., & Morgan, N. G. (2007) · Clinical Science · doi:10.1042/cs20060115 · Cited by 155
Therapeutic Approaches to Preserve Islet Mass in Type 2 Diabetes
Baggio, L. L., & Drucker, D. J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.110104.115624 · Cited by 149
Self-citationObesity and genetics regulate microRNAs in islets, liver, and adipose of diabetic mice
Zhao, E., Keller, M. P., Rabaglia, M. E., Oler, A. T., Stapleton, D. S., Schueler, K. L., Neto, E. C., Moon, J. Y., Wang, P., Wang, I.-M., et al. (2009) · Mammalian Genome · doi:10.1007/s00335-009-9217-2 · Cited by 148
‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis
Lonardo, A., Carani, C., Carulli, N., & Loria, P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.03.005 · Cited by 149
Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery
Cummings, D. E., Overduin, J., Foster-Schubert, K. E., & Carlson, M. J. (2007) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2007.02.003 · Cited by 140
In beta-cells, mitochondria integrate and generate metabolic signals controlling insulin secretion
Maechler, P., Carobbio, S., & Rubi, B. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.12.006 · Cited by 140
“According to all these actions, GLP-1 and biologically active related molecules are of interest for the treatment of diabetes (Drucker, 2003b; Gromada, Brock, Schmitz, & Rorsman, 2004).”
BackgroundCaveolin-1 Regulates Cellular Trafficking and Function of the Glucagon-Like Peptide 1 Receptor
Syme, C. A., Zhang, L., & Bisello, A. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0178 · Cited by 138
Kim, K.-S., Egan, J. M., & Jang, H.-J. (2014) · Diabetologia · doi:10.1007/s00125-014-3326-5 · Cited by 137
Luginbuhl, K. M., Schaal, J. L., Umstead, B. R., Mastria, E. M., Li, X., Banskota, S., Arnold, S., Feinglos, M. N., D’Alessio, D. A., & Chilkoti, A. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0078 · Cited by 130
Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat–Fed Mice
Lamont, B. J., & Drucker, D. J. (2008) · Diabetes · doi:10.2337/db07-1202 · Cited by 127
Self-citationGlucagon‐like peptide 1 receptor stimulation as a means of neuroprotection
Harkavyi, A., & Whitton, P. S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00486.x · Cited by 125
Singh, S., Sharma, R. K., Malhotra, S., Pothuraju, R., & Shandilya, U. K. (2017) · Beneficial Microbes · doi:10.3920/bm2016.0090 · Cited by 124
Grieve, D. J., Cassidy, R. S., & Green, B. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00376.x · Cited by 121
Surgical Treatment of Morbid Obesity
Crookes, P. F. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144928 · Cited by 115
GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts
Xu, G., Kaneto, H., Lopez-Avalos, M. D., Weir, G. C., & Bonner-Weir, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.11.007 · Cited by 115
Incretin hormone mimetics and analogues in diabetes therapeutics
Green, B. D., & Flatt, P. R. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.003 · Cited by 125
Oral antidiabetic agents in type 2 diabetes
Levetan, C. S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x178766 · Cited by 125
Lu, S.-S., Yu, Y.-L., Zhu, H.-J., Liu, X.-D., Liu, L., Liu, Y.-W., Wang, P., Xie, L., & Wang, G.-J. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0419 · Cited by 112
Exendin-4 modulates diabetes onset in nonobese diabetic mice
Hadjiyanni, I., Baggio, L. L., Poussier, P., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2007-1137 · Cited by 110
Self-citationEmerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 109
Self-citationGlucagon‐Like Peptide‐1: Regulation of Insulin Secretion and Therapeutic Potential
Gromada, J., Brock, B., Schmitz, O., & Rorsman, P. (2004) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2004.t01-1-pto950502.x · Cited by 105
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0014-9 · Cited by 112
Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery
Cummings, D. E., Overduin, J., Shannon, M. H., & Foster‐Schubert, K. E. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2005.03.208 · Cited by 107
Muzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 125
GREIG, N. H., MATTSON, M. P., PERRY, T., CHAN, S. L., GIORDANO, T., SAMBAMURTI, K., ROGERS, J. T., OVADIA, H., & LAHIRI, D. K. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.018 · Cited by 98
Aviv, V., Meivar-Levy, I., Rachmut, I. H., Rubinek, T., Mor, E., & Ferber, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.017608 · Cited by 94
Banskota, S., Yousefpour, P., Kirmani, N., Li, X., & Chilkoti, A. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.11.012 · Cited by 94
Hu, Y., Riesland, L., Paterson, A. J., & Kudlow, J. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401547200 · Cited by 95
GLP-1(7-36)-amide and Exendin-4 Stimulate the HPA Axis in Rodents and Humans
Gil-Lozano, M., Pérez-Tilve, D., Alvarez-Crespo, M., Martís, A., Fernandez, A. M., Catalina, P. A. F., Gonzalez-Matias, L. C., & Mallo, F. (2010) · Endocrinology · doi:10.1210/en.2009-0915 · Cited by 93
Incretin Effects on β-Cell Function, Replication, and Mass
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s230 · Cited by 92
“ANIMAL DATA—As discussed above, the acute effect of GLP-1 on the b-cells is potentiation of glucose-dependent insulin secretion (18).”
BackgroundHuising, M. O., van der Meulen, T., Vaughan, J. M., Matsumoto, M., Donaldson, C. J., Park, H., Billestrup, N., & Vale, W. W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913610107 · Cited by 90
Timper, K., Grisouard, J., Sauter, N. S., Herzog-Radimerski, T., Dembinski, K., Peterli, R., Frey, D. M., Zulewski, H., Keller, U., Müller, B., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00100.2012 · Cited by 88
Increased Pancreatic β-Cell Proliferation Mediated by CREB Binding Protein Gene Activation
Hussain, M. A., Porras, D. L., Rowe, M. H., West, J. R., Song, W.-J., Schreiber, W. E., & Wondisford, F. E. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02353-05 · Cited by 88
Shrestha, N., Shahbazi, M., Araújo, F., Mäkilä, E. M., Raula, J., Kauppinen, E. I., Salonen, J., Sarmento, B. F. C. C., Hirvonen, J. J., & Santos, H. A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.045 · Cited by 100
Knoch, K.-P., Meisterfeld, R., Kersting, S., Bergert, H., Altkrüger, A., Wegbrod, C., Jäger, M., Saeger, H.-D., & Solimena, M. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2005.12.008 · Cited by 85
Liu, W. J., Jin, H. Y., Lee, K. A., Xie, S. H., Baek, H. S., & Park, T. S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01272.x · Cited by 84
Froud, T., Faradji, R. N., Pileggi, A., Messinger, S., Baidal, D. A., Ponte, G. M., Cure, P. E., Monroy, K., Mendez, A., Selvaggi, G., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e31817c4ab3 · Cited by 84
Katagiri, D., Hamasaki, Y., Doi, K., Okamoto, K., Negishi, K., Nangaku, M., & Noiri, E. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013020134 · Cited by 80
Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes
Sutton, J. M., Clark, D. E., Dunsdon, S. J., Fenton, G., Fillmore, A., Harris, N. V., Higgs, C., Hurley, C. A., Krintel, S. L., MacKenzie, R. E., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.054 · Cited by 79
Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
D’Alessio, D. A., & Vahl, T. P. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00014.2004 · Cited by 80
Moffett, R. C., Vasu, S., Thorens, B., Drucker, D. J., & Flatt, P. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096863 · Cited by 75
Self-citationCinnamtannin A2, a Tetrameric Procyanidin, Increases GLP-1 and Insulin Secretion in Mice
Yamashita, Y., OKABE, M., Natsume, M., & Ashida, H. (2013) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.130095 · Cited by 82
Apoptosis of Beta Cells in Diabetes Mellitus
Rachakatla, A., Mudigonda, S., Kumar, K., & Hanumanth, S. R. (2014) · DNA and Cell Biology · doi:10.1089/dna.2014.2352 · Cited by 81
Emerging treatment options for type 2 diabetes
Piya, M. K., Tahrani, A. A., & Barnett, A. H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03711.x · Cited by 72
Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans
Meier, J. J., Butler, A. E., Galasso, R., RIZZA, R. A., & Butler, P. C. (2006) · Diabetologia · doi:10.1007/s00125-006-0410-5 · Cited by 77
Remission of Type 2 Diabetes Mellitus after Bariatric Surgery: Fact or Fiction?
Tsilingiris, D., Koliaki, C. C., & Kokkinos, A. D. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16173171 · Cited by 85
Role of Mitochondria in β-cell Function and Dysfunction
Maechler, P., Li, N., Casimir, M., Vetterli, L., Frigerio, F., & Brun, T. (2010) · Advances in Experimental Medicine and Biology · doi:10.1007/978-90-481-3271-3_9 · Cited by 68
Li, D., Yin, X., Zmuda, E. J., Wolford, C. C., Dong, X., White, M. F., & Hai, T. (2008) · Diabetes · doi:10.2337/db07-0717 · Cited by 68
Bariatric Surgery as a Novel Treatment for Type 2 Diabetes Mellitus: A Systematic Review
Meijer, R. I. (2011) · Archives of Surgery · doi:10.1001/archsurg.2011.134 · Cited by 67
Gα i/o -coupled receptor signaling restricts pancreatic β-cell expansion
Berger, M., Scheel, D. W., Macias, H., Miyatsuka, T., Kim, H., Hoang, P., Ku, G. M., Honig, G., Liou, A., Tang, Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319378112 · Cited by 67
Emerging Concepts in the Pathophysiology of Type 2 Diabetes Mellitus
Surampudi, P. N., John‐Kalarickal, J., & Fonseca, V. A. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20113 · Cited by 95
Şimşek, N., Kaya, M., Kara, A., Can, I., Karadeniz, A., & Kalkan, Y. (2012) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2012.02.002 · Cited by 70
Hogan, A. R., Pileggi, A., & Ricordi, C. (2007) · Frontiers in bioscience · doi:10.2741/2755 · Cited by 75
In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update
Kury, L. T. A., Abdoh, A., Ikbariah, K., Sadek, B. S., & Mahgoub, M. (2021) · Molecules · doi:10.3390/molecules27010182 · Cited by 79
Nutrients related to GLP1 secretory responses
Mansour, A., Hosseini, S., Larijani, B. A., Pajouhi, M., & Mohajeri‐Tehrani, M. R. (2013) · Nutrition · doi:10.1016/j.nut.2012.11.015 · Cited by 75
Welters, H. J., Diakogiannaki, E., Mordue, J. M., Tadayyon, M., Smith, S. A., & Morgan, N. G. (2006) · APOPTOSIS · doi:10.1007/s10495-006-7450-7 · Cited by 69
Diabetes as a disease of endoplasmic reticulum stress
Thomas, S. E., Dalton, L. E., Daly, M., Malzer, E., & Marciniak, S. J. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1132 · Cited by 65
de Carvalho, C. P., Marin, D. M., de Souza, A. L., Pareja, J. C., Chaim, É. A., de Barros-Mazon, S., da Silva, C. A., Geloneze, B., Muscelli, E., & Alegre, S. M. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9678-5 · Cited by 64
Exendin-4 induction of cyclin D1 expression in INS-1 β-cells: involvement of cAMP-responsive element
Kim, M.-J., Kang, J.-H., Park, Y. G., Ryu, G. R., Ko, S. H., Jeong, I.-K., Koh, K.-H., Rhie, D.-J., Yoon, S. H., Hahn, S. J., et al. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06480 · Cited by 60
Interventions to Preserve Beta-Cell Function in the Management and Prevention of Type 2 Diabetes
Page, K. A., & Reisman, T. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0363-2 · Cited by 65
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
Dozier, K. C., Cureton, E. L., Kwan, R. O., Curran, B., Sadjadi, J., & Victorino, G. P. (2009) · Peptides · doi:10.1016/j.peptides.2009.06.019 · Cited by 58
“Injury to myocytes and pancreatic beta-cells after an ischemic insult is attenuated by GLP-1 [3,12,13,33].”
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
Regeneration of pancreatic islets in vivo by ultrasound-targeted gene therapy
Chen, S., Shimoda, M., Wang, M.-Y., Ding, J., Noguchi, H., Matsumoto, S., & Grayburn, P. A. (2010) · Gene Therapy · doi:10.1038/gt.2010.85 · Cited by 60
Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin
List, J. F., He, H., & Habener, J. F. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.02.007 · Cited by 65
Spinnler, R., Gorski, T., Stolz, K., Schuster, S., Garten, A., Beck-Sickinger, A. G., Engelse, M. A., de Koning, E. J. P., Körner, A., Kiess, W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054106 · Cited by 55
Differential Stimulation of Insulin Secretion by GLP-1 and Kisspeptin-10
Schwetz, T. A., Reissaus, C. A., & Piston, D. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113020 · Cited by 54
Impact of Bariatric Surgery on Comorbidities
Kaul, A., & Sharma, J. (2011) · Surgical Clinics of North America · doi:10.1016/j.suc.2011.08.003 · Cited by 64
Jimenez‐Feltström, J., Lundquist, I., & Salehi, A. A. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-1013-4 · Cited by 54
Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability and in Vivo Potency
Sebokova, E., Christ, A. D., Wang, H., Sewing, S., Dong, J. Z., Taylor, J., Cawthorne, M. A., & Culler, M. D. (2010) · Endocrinology · doi:10.1210/en.2009-1459 · Cited by 51
Gastrointestinal surgery as treatment for type 2 diabetes
Moo, T.-A. S., & Rubino, F. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f88a0a · Cited by 53
Salehi, A., Meidute Abaraviciene, S., Jimenez-Feltstrom, J., Östenson, C.-G., Efendic, S., & Lundquist, I. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002165 · Cited by 49
Metadata
- Authors
- Drucker, D. J.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Drucker, Daniel J.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2003-12-01
- Volume
- 144
- Issue
- 12
- Pages
- 5145-5148
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2141880555
- Cited by
- 274
- References
- 39
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 7 · 2023: 3 · 2022: 9 · 2021: 8 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 12 · 2016: 10 · 2015: 6 · 2014: 10 · 2013: 18 · 2012: 7
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- glucagon-like peptide-1, beta-cell proliferation, beta-cell apoptosis, type 2 diabetes, beta-cell mass, islet neogenesis, insulin secretion, insulin resistance, growth factors, islet transplantation, beta-cell preservation, monounsaturated fatty acids, hyperglycemia, parathyroid hormone-related protein, gastrin
- MeSH terms
- Animals, Cell Division, Glucagon, Humans, Islets of Langerhans, Peptide Fragments, Protein Precursors, Apoptosis, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.